Scenic Biotech, a pioneer in modifier therapies for severe diseases, appointed Roland W. Bürli, PhD, as Chief Scientific Officer (CSO), effective September 1, 2025. At Scenic, Bürli will oversee the ...

Scenic Biotech is advancing modifier therapy, a radical new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance ...

Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September 09, ...

Liam has been a Features writer for Game Rant since 2021. He's a life-long gaming enthusiast, and started covering game news in 2019. Liam has a preference for melee-focused action games, and enjoys ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Kotlin was designed to bring more flexibility and flow to programming in the JVM. Here's an in-depth look at how Kotlin makes working with classes and objects easier and introduces coroutines to ...

Ocugen (NASDAQ:OCGN) has secured a $30M debt funding from Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. The credit facility, which has a term of 4 years, provided $30M fully ...

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...